Effectiveness of the P2X3 Antagonist Gefapixant for Refractory Atopic Cough: A Retrospective Cohort Study
Yoshihisa Ishiura, Shosaku Nomura, Noriyuki Ohkura, Johsuke Hara, Masaki Fujimura, Tomoki Ito · 2026
Read Effectiveness of the P2X3 Antagonist Gefapixant for Refractory Atopic Cough: A Retrospective Cohort Study by Yoshihisa Ishiura, Shosaku Nomura, Noriyuki Ohkura, Johsuke Hara, Masaki Fujimura, Tomoki Ito (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13242768.txt.
Description
Yoshihisa Ishiura and co-authors present a 2026 retrospective study of gefapixant for stubborn atopic cough. This cough type stems from oversensitive airway nerve fibers. The drug blocks a receptor that amplifies those fiber signals and is already approved for refractory cough.
Twenty-three patients whose cough had responded only partly to an allergy drug received the new treatment. Lung function, inflammation markers, and allergy blood values stayed unchanged. Patient-rated cough severity and a cough quality questionnaire both improved significantly. Sensitivity of the cough reflex to a chili compound also fell. The authors suggest receptor blockade calms the oversensitive fibers themselves. They present the option as promising for a group with few alternatives.
Catalog record
| CREATOR | Yoshihisa Ishiura, Shosaku Nomura, Noriyuki Ohkura, Johsuke Hara, Masaki Fujimura, Tomoki Ito |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |